Abstract ObjectiveTo evaluate the clinical efficacy and safety of Losec combined with Stilamin for upper gastrointestinal bleeding.M ethodsFrom January 2011 to January 2017,100 patients with upper gastrointestinal bleeding were randomly divided into observation group and control group.There were 50 cases in each group.The observation group was treated with Losec combined with Stilamin and the control group was treated with Losec alone.At the same time,two groups of patients were
received:fasting,rehydration and hemostatic agents and other conventional conservative treatment.The hospitalization time,hospitalization cost,blood transfusion,emergency surgery rate,3-month non-cure rate,and adverse events were recorded and compared.ResultsThe hospitalization cost of the observation group was significantly lower than thatof the control group,the differencewas statistically significant[(6.78±0.74)d vs.(9.62 ±1.26)d](P<0.01);the hospitalization cost of the observation group was significantly lower than that of the control group,the difference was statistically significant[(14361.64±3033.71)yuan vs. (18225.80±7249.82)yuan](P<0.01).The blood transfusion in the observation group was significantly lower than that in the control group[(2.43±1.55)U vs.(3.36±1.68)U](P<0.05).The emergency surgery rate in the observation group was significantly lower than that in the controlgroup (4.00%vs.10.00%)(P<0.05);The 3-month non-cure rate in the observation group was significantly lower than that in the control group(4.00%vs.6.00%)(P<0.05);therewasno significantdifference in the incidenceofadverse reactionsbetween the twogroups(P>0.05).ConclusionCompared with losecine,the combination of Stilamin and Losec significantly reduced hospital stay,reduced hospitalization costs,reduced blood transfusion,reduced emergency surgery and 3-month non-healing rates.
|